The millions of Americans who have been suffering from migraine could possibly find some solace in a new source of hope. The very first drug that is aimed at preventing the headaches that arises as a result of migraine has recently gained approval from U.S. Food and Drug Administration.
The Drug Works by Blocking a Key Brain Chemical that Sends out Pain Signals
Researchers have discovered that the injected drug which has been named Aimovig (erenumab), can prevent migraines if other conventional treatments have failed to do so.
Dr. Eric Bastings, deputy director of the division of neurology products in the FDA’s Center for Drug Evaluation and Research, said in an agency news release said that Aimovig offers the migraine-affected patients with a novel option of reducing the number of days with migraine. He further said that there is a need for new treatments for this painful and often debilitating medical condition.
Millions of people suffer from the light and sound sensitivity, throbbing pain, and nausea that could accompany migraines. Aimovig works by blocking a key brain “neurotransmitter” chemical that gives out pain signals, as explained by a team of researchers who has presented their study findings last month at the annual meeting of the American Academy of Neurology (AAN) in Los Angeles.
Working together with a group of people with tough-to-treat migraine, the research discovered that the drug diminished the average number of monthly migraine headaches by more than 50 percent for nearly one third of study participants. The approval by the FDA was spurred by the outcome of studies just like that one.